[Ketamine in acute and severe major depressive disorder].
La Presse Médicale. 2014-05-01; 43(5): 492-500
DOI: 10.1016/j.lpm.2013.11.013
Lire sur PubMed
1. Presse Med. 2014 May;43(5):492-500. doi: 10.1016/j.lpm.2013.11.013. Epub 2014 Mar
12.
[Ketamine in acute and severe major depressive disorder].
[Article in French]
Brittner M(1), Micoulaud-Franchi JA(2), Richieri R(2), Boyer L(3), Adida M(2),
Lancon C(2), Fond G(4).
Author information:
(1)CHU de Montpellier, université Montpellier 1, service universitaire de
psychiatrie, Inserm 1061, 34000 Montpellier, France.
(2)Hôpital Sainte-Marguerite, service hospitalo-universitaire de psychiatrie,
13009 Marseille, France.
(3)Faculté de médecine, laboratoire de santé publique, EA 3279, 13385 Marseille
cedex 05, France.
(4)Groupe des hôpitaux universitaires de Mondor, université Paris-Est-Créteil,
pôle de psychiatrie, Eq psychiatrie génétique, fondation FondaMental, fondation
de coopération scientifique en santé mentale, DHU Pepsy, Inserm U955, 40, rue de
Mesly, 94010 Créteil, France. Electronic address: .
CONTEXT: Depression is a frequent, severe and expensive illness. Approximately
20% of depressive episodes are resistant to classic antidepressants.
Glutamatergic antagonists, in particular ketamine, established a new, rapid and
robust therapeutic approach in resistant depression.
RESULTS: The main results in the literature show a rapid and robust
antidepressant effect of ketamine, with infra-anesthesic posology (0.5mg/kg)
administered in intravenous way. Positive effects are observed on depressive
symptoms, suicidal thoughts, and there is a potential synergic action when used
in the induction of anesthesia for electroconvulsive therapy. However, effects
only last shortly. Side effects are mostly reversible and of mild intensity, no
severe consequences were reported.
LIMITS: Limits are the lack of power of the included studies, due to small sample
sizes, and the scarcity of studies. Misuse of ketamine is an important issue to
be taken into account, and few data about ketamine addiction potential and its
long-term effects are published at the moment.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
DOI: 10.1016/j.lpm.2013.11.013
PMID: 24630265 [Indexed for MEDLINE]